Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months (JAMA) In this retrospective cohort study, insulin-treated patients with diabetes selected by physicians for real-time continuous glucose monitoring compared with noninitiators had significant improvements in hemoglobin A1c and reductions in emergency department visits and hospitalizations for hypoglycemia, but no significant change in emergency department visits or hospitalizations for hyperglycemia or for any reason (JAMA) Adiposity, glucose and lipid control over the follow-up are likely to influence both. Enhanced adiposity seems paramount for the onset of hepatic steatosis in T1D patients alike in healthy youths (Diabetes/Metabolism Research and Reviews) The existing decision models for T2DM are heterogeneous in terms of the level of detail in the classification of health states. Thus, more attention should be focused on balancing the desired level of complexity against the required level of transparency in the development of T2DM decision models (Acta Diabetologica) These data indicate prevalent early adoption of oral semaglutide in primary care, demonstrate real-world improvements in glycaemic control, and identify potential treatment gaps (Diabetes, Obesity and Metabolism) Our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients (Acta Diabetologica) Our data show the superior performance of cHbA1c compared with eHbA1c and GMI at reflecting laboratory HbA1c. These data indicate that cHbA1c can be potentially used instead in laboratory HbA1c, at least in younger individuals with T1D (Diabetes Technology and Therapeutics) Bariatric surgery is associated with an increased incidence of hypoglycaemia-related events in patients without baseline diabetes, especially during the first years after treatment (Diabetes, Obesity and Metabolism)
|